Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.62 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.62 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.59 |
| ▸ | TUBB | P07437 | 2/20 | 0.59 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.59 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.59 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.59 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.59 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.59 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8500772 | 1.00 | CYP1A2 (0.79) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL9364577 | 0.91 | CYP1A2 (0.96) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL1493250 | 0.89 | CYP1A2 (1.00) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL8625485 | 0.88 | ALDH1A1 (0.86) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL8626158 | 0.88 | ALDH1A1 (0.64) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL6654012 | 0.86 | SLC22A6 (0.59) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL4825052 | 0.85 | CYP1A2 (0.71) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL6650962 | 0.84 | TUBB4A (0.73) | SLC22A6SLC22A8TUBB4ATUBBTUBA3C | |
| SCHEMBL7369813 | 0.84 | SLC22A6 (0.89) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL6872165 | 0.84 | TSHR (0.81) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470723-B2 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1361210-B1 | Novel immunotherapeutic agents and their use in the reduction of cytokine levels | CELGENE CORP (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080114061-A1 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION | 2008-05-15 | — | — | US | disclosed |
| US-7312241-B2 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1799634-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1603864-A4 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORP (US) | 2007-04-11 | — | — | EP | disclosed |
| US-7019030-B2 | Cyano and carboxy derivatives of substituted styrenes; inhibitors of tumor necrosis factor alpha, nuclear factor kappa B, and phosphodiesterase | CELGENE CORPORATION (US) | 2006-03-28 | — | — | US | disclosed |
| WO-2006026747-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1603864-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050107339-A1 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION | 2005-05-19 | — | — | US | disclosed |
| US-20050014727-A1 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION | 2005-01-20 | — | — | US | disclosed |
| WO-2004078144-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040019106-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1361210-A2 | Novel immunotherapeutic agents and their use in the reduction of cytokine levels | CELGENE CORPORATION (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20030045726-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2003-03-06 | — | — | US | disclosed |
| US-6479554-B2 | CYANO AND CARBOXY DERIVATIVES OF SUBSTITUTED STYRENES ARE INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA , NUCLEAR FACTOR KAPPA B, AND PHOSPHODIESTERASE AND CAN BE USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, INFLAMMATORY CONDITIONS ETC. | CELGENE CORPORATION | 2002-11-12 | — | — | US | disclosed |
| US-20010056107-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2001-12-27 | — | — | US | disclosed |
| US-6262101-B1 | ALPHA-PYRROLIDINE, IMIDAZOLE AND THIOPHENE-SUBSTITUTED STYRENE DERIVATIVES; INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA, NUCLEAR FACTOR KAPPA B, AND PHOSPHODIESTERASE | CELGENE CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6130226-A | Immunotherapeutic agents | CELGENE CORPORATION (US) | 2000-10-10 | — | — | US | disclosed |
| US-5929117-A | COMPOUNDS WHICH MEDIATE ACTION OF PHOSPHODIESTERASE AND FORMATION OF TUMOR NECROSIS FACTOR AND NUCLEAR FACTORS | CELGENE CORPORATION (US) | 1999-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107339-A1 | Diphenylethylene compounds and uses thereof | VHL, TNF, PTGES | CYP1A2 139/4885CYP2C19 349/4885CYP3A4 356/4885 |
| US-20030045726-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | CYP1A2 3471/4885CYP2C19 4166/4885CYP3A4 3495/4885 |
| US-20040019106-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | CYP1A2 3471/4885CYP2C19 4166/4885CYP3A4 3495/4885 |
| US-20080114061-A1 | Diphenylethylene compounds and uses thereof | VHL, TNF, PTGES | CYP1A2 139/4885CYP2C19 349/4885CYP3A4 356/4885 |
| US-20010056107-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | CYP1A2 3471/4885CYP2C19 4166/4885CYP3A4 3495/4885 |
| US-20050014727-A1 | Diphenylethylene compounds and uses thereof | VHL, TNF, PTGES | CYP1A2 139/4885CYP2C19 349/4885CYP3A4 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.